Pauline D. B.
- Country
- Belgium
- Department
- Pediatric Gastro-Enterology
Research Overview
- A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
- Phase 3 Multicenter Open-Label Study on Long-Term Efficacy and Safety of Mirikizumab in Pediatric Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease
- Long-term Safety Evaluation of Guselkumab in Pediatric Patients with Moderately to Severely Active Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
Data & Insights
Has run more than one trial at 41 of 72 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in treating pediatric inflammatory bowel diseases, with particular emphasis on both Crohn's disease and ulcerative colitis.
- Moderately to severely active Crohn's disease in children
- Pediatric ulcerative colitis management
- Chronic inflammatory bowel conditions
Their research encompasses innovative therapeutic approaches for young patients with inflammatory bowel conditions.
Therapeutic Applications
The investigator focuses on evaluating novel biological therapies including IL-23 inhibitors and targeted immunological treatments.
- Intravenous induction treatments
- Subcutaneous maintenance therapy
- Long-term treatment strategies
Their work involves assessing therapeutic efficacy in pediatric populations with inflammatory conditions.
Clinical Expertise
The investigator's clinical focus includes pediatric gastroenterology and the treatment of autoimmune disorders in young patients.
- Clinical remission assessment
- Endoscopic response evaluation
- Pharmacokinetic studies in children
Their expertise extends to managing complex inflammatory conditions in pediatric populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.